<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548638" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548638/" /><meta name="ncbi_pagename" content="Crizotinib - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Crizotinib - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Crizotinib" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/10/30" /><meta name="citation_pmid" content="31643950" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548638/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Crizotinib" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/10/30" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548638/" /><meta name="description" content="Crizotinib is a selective tyrosine kinase receptor inhibitor used in the therapy of selected cases of advanced non-small cell lung cancer. Crizotinib is associated with transient elevations in serum aminotransferase levels during treatment and rare instances of clinically apparent acute liver injury that can be severe and even fatal." /><meta name="og:title" content="Crizotinib" /><meta name="og:type" content="book" /><meta name="og:description" content="Crizotinib is a selective tyrosine kinase receptor inhibitor used in the therapy of selected cases of advanced non-small cell lung cancer. Crizotinib is associated with transient elevations in serum aminotransferase levels during treatment and rare instances of clinically apparent acute liver injury that can be severe and even fatal." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548638/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Crizotinib/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548638/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE89C02A04664A810000000005A2019C.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548638_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548638_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Corticosteroids/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Crofelemer/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548638_"><span class="title" itemprop="name">Crizotinib</span></h1><p class="small">Last Update: <span itemprop="dateModified">October 30, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Crizotinib.OVERVIEW"><h2 id="_Crizotinib_OVERVIEW_">OVERVIEW</h2><div id="Crizotinib.Introduction"><h3>Introduction</h3><p>Crizotinib is a selective tyrosine kinase receptor inhibitor used in the therapy of selected cases of advanced non-small cell lung cancer. Crizotinib is associated with transient elevations in serum aminotransferase levels during treatment and rare instances of clinically apparent acute liver injury that can be severe and even fatal.</p></div><div id="Crizotinib.Background"><h3>Background</h3><p>Crizotinib (kriz oh&#x02019; ti nib) is an orally available, small molecule inhibitor of the tyrosine kinase receptor of mutated anaplastic lymphoma kinase (ALK), which is the result of a chromosomal translocation found in about 5% of lung cancers. Patients with non-small cell lung cancer with the ALK mutation often respond to crizotinib therapy with shrinkage of the tumor and apparent improvement in survival. Crizotinib received accelerated approval for use in the United States in 2011 for the treatment of advanced non-small cell lung cancer with the ALK translocation (a test for this genetic rearrangement was also approved). Crizotinib is available in capsules of 200 and 250 mg under the brand name Xalkori. The recommended dose is 250 mg by mouth twice daily, with dose modification based upon tolerance. Side effects are common and include diarrhea, nausea, vomiting, anorexia, fatigue, constipation, visual disturbances and edema. Uncommon, but potentially serious side effects include interstitial lung disease, QTc interval prolongation and bradycardia.</p></div><div id="Crizotinib.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In large early clinical trials, elevations in serum aminotransferase levels occurred in up to 57% of patients treated with standard doses of crizotinib, were greater than 5 times ULN in 6% of patients, and led to early discontinuation of therapy in 2% to 4% of patients. Serum aminotransferase elevations typically arose after 4 to 12 weeks of treatment, but usually without jaundice or alkaline phosphatase elevations. Restarting crizotinib after resolution of the aminotransferase abnormalities can be done starting with a reduced dose. Most cases of liver injury due to crizotinib have been minimally or not symptomatic, and the injury resolved within 1 to 2 months of stopping the drug (Case 1). However, cases with jaundice and symptoms during crizotinib therapy have been reported which were fatal in 0.1% of treated patients (Case 2). The severe cases of liver injury due to crizotinib typically arose within 2 to 6 weeks of starting therapy and presented with marked elevations in serum aminotransferase levels followed by jaundice, progressive hepatic dysfunction, coagulopathy, encephalopathy and death. For these reasons, routine periodic monitoring of liver tests at 2 to 4 week intervals during therapy is recommended.</p><p>Likelihood score: C (probable cause of clinically apparent acute liver injury).</p></div><div id="Crizotinib.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of the liver injury due to crizotinib is unknown. Crizotinib is metabolized in the liver largely via CYP 3A4, and liver injury may be due to accumulation of a toxic or immunogenic intermediate. Crizotinib is susceptible to drug-drug interactions with medications that inhibit or induce CYP 3A4.</p></div><div id="Crizotinib.Outcome_and_Management"><h3>Outcome and Management</h3><p>Routine monitoring of liver tests are recommended for patients starting crizotinib, including serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a>, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> and bilirubin every 2 weeks for the first 2 months and monthly thereafter and as clinically indicated. Serum aminotransferase elevations above 5 times the upper limit of normal (if confirmed) should lead to dose interruption. If changes persist, are severe, or reoccur on restarting, crizotinib should be discontinued. There have been reports of acute liver failure, but not of chronic hepatitis or vanishing bile duct syndrome due to crizotinib. Patients with liver abnormalities during crizotinib therapy may tolerate other kinase inhibitors active against non-small cell lung cancer such as erlotinib or gefitinib.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/">Antineoplastic Agents</a>, <a href="/books/n/livertox/ProteinKinaseInhibit/">Protein Kinase Inhibitors</a></p></div></div><div id="Crizotinib.CASE_REPORTS"><h2 id="_Crizotinib_CASE_REPORTS_">CASE REPORTS</h2><div id="Crizotinib.Case_1._Serum_aminotransferas"><h3>Case 1. Serum aminotransferase elevations during crizotinib therapy.</h3><p>[Modified from: Ripault MP, Pinzani V, Fayolle V, Pageaux GP, Larrey D. Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose. Clin Res Hepatol Gastroenterol 2013; 37: e21-3. <a href="https://www.ncbi.nlm.nih.gov/pubmed/23182672" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 69 year old woman with metastatic non-small cell lung cancer developed fatigue 2 months after starting crizotinib (500 mg daily). She had no history of liver disease, risk factors for viral hepatitis or alcohol abuse. Her only other medications were low doses of aspirin (75 mg daily). Physical examination was normal. Laboratory tests showed normal serum bilirubin, but <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 159 U/L (4.8 times ULN), <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> 98 U/L (3 times ULN), but normal alkaline phosphatase, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.gamma-glutamyl-transpeptidase-ggt-/">GGT</a> and prothrombin time. Her liver tests had been normal before starting crizotinib (Table). Tests for hepatitis A, B, C and E, CMV, Epstein Barr virus and herpes simplex virus were negative and autoantibodies were not present. Imaging of the liver was normal. Crizotinib was stopped and liver tests improved and were near normal one month later when crizotinib was restarted. Two weeks later, serum aminotransferase levels were again elevated and crizotinib was permanently discontinued.</p><div id="Crizotinib.Key_Points1"><h4>Key Points</h4><div id="Crizotinib.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548638/table/Crizotinib.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Crizotinib.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Crizotinib (500 mg daily)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=~5)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">1+ (serum enzyme elevations without jaundice)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</td><td rowspan="1" colspan="1" style="vertical-align:top;">8 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">6 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Aspirin</td></tr></tbody></table></div></div></div><div id="Crizotinib.Laboratory_Values1"><h4>Laboratory Values</h4><div id="Crizotinib.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548638/table/Crizotinib.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Crizotinib.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Crizotinib.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting*</th><th id="hd_h_Crizotinib.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Crizotinib.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(x ULN)</th><th id="hd_h_Crizotinib.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P</th><th id="hd_h_Crizotinib.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Crizotinib.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Crizotinib.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Crizotinib.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Pre</td><td headers="hd_h_Crizotinib.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">&#x0003c;1</td><td headers="hd_h_Crizotinib.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Crizotinib.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">3 weeks</td><td headers="hd_h_Crizotinib.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Pre</td><td headers="hd_h_Crizotinib.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1.2</td><td headers="hd_h_Crizotinib.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Crizotinib.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">8 weeks</td><td headers="hd_h_Crizotinib.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Crizotinib.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">4.8</td><td headers="hd_h_Crizotinib.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Crizotinib stopped</td></tr><tr><td headers="hd_h_Crizotinib.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">10 weeks</td><td headers="hd_h_Crizotinib.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Crizotinib.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">3.2</td><td headers="hd_h_Crizotinib.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Crizotinib.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">13 weeks</td><td headers="hd_h_Crizotinib.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">5 weeks</td><td headers="hd_h_Crizotinib.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1.3</td><td headers="hd_h_Crizotinib.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Crizotinib restarted</td></tr><tr><td headers="hd_h_Crizotinib.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">15 [2] weeks</td><td headers="hd_h_Crizotinib.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Crizotinib.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">5.3</td><td headers="hd_h_Crizotinib.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Crizotinib restopped</td></tr><tr><td headers="hd_h_Crizotinib.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">16 [3] weeks</td><td headers="hd_h_Crizotinib.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">1 week</td><td headers="hd_h_Crizotinib.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">2.7</td><td headers="hd_h_Crizotinib.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Crizotinib.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">17 [4] weeks</td><td headers="hd_h_Crizotinib.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Crizotinib.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1.4</td><td headers="hd_h_Crizotinib.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Crizotinib.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">22 [9] weeks</td><td headers="hd_h_Crizotinib.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">7 weeks</td><td headers="hd_h_Crizotinib.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">&#x0003c;1</td><td headers="hd_h_Crizotinib.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Crizotinib.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Crizotinib.T2_1_1_1_1 hd_h_Crizotinib.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Crizotinib.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1</b></td><td headers="hd_h_Crizotinib.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Crizotinib.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Crizotinib.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div><p>*Values in brackets represent number of weeks after restarting crizotinib.</p></div><div id="Crizotinib.Comment1"><h4>Comment</h4><p>Elevations in serum aminotransferase levels occur in up to 57% of patients treated with crizotinib, but they are usually mild and self-limited. Elevations above 5 times the upper limit (approximately 200 U/L) arise in 5% to 17% of patients and even then may not require drug discontinuation. In this patient, the serum aminotransferase elevations were mild-to-moderate in severity (<a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> never rose above 200 U/L), but were associated with symptoms of fatigue. The elevations resolved rapidly upon stopping therapy, but then reappeared with restarting even at a lower dose. The patient was never jaundiced, and alkaline phosphatase and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.gamma-glutamyl-transpeptidase-ggt-/">GGT</a> levels were normal. The symptoms were not clearly described and may not have been due to the liver injury, as crizotinib can cause fatigue independent of liver injury. In most patients (but not this one), serum ALT elevations resolve spontaneously either with continuation of therapy or with stopping and restarting at a lower dose.</p></div></div><div id="Crizotinib.Case_2._Fatal_liver_injury_du"><h3>Case 2. Fatal liver injury during crizotinib therapy.</h3><p>[Modified from: van Geel RM, Hendrikx JJ, Vahl JE, van Leerdam ME, van den Broek D, Huitema AD, Beijnen JH,et al. Crizotinib-induced fatal fulminant liver failure. Lung Cancer 2016; 93: 17-9. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26898609" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 62 year old woman with metastatic non-small cell lung cancer [NSCLC] developed abnormal <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> levels 17 days after starting crizotinib [250 mg twice daily], but was continued on therapy until one week later when liver test results were found to have worsened (Table). Crizotinib was stopped but she developed diarrhea, fatigue and jaundice one week later and was admitted. She had no history of liver disease, did not drink alcohol and was taking no other potentially hepatoxic medications. Tests for hepatitis A, B, C and E were negative and ultrasound of the abdomen showed no evidence of biliary obstruction or hepatic masses. She was treated for hepatic failure but devleoped coma, multiorgan failure and died 40 days after starting and 16 days after stopping crizotinib.</p><div id="Crizotinib.Key_Points2"><h4>Key Points</h4><div id="Crizotinib.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548638/table/Crizotinib.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Crizotinib.T3_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><b>Medication:</b></td><td rowspan="1" colspan="1" style="vertical-align:top;">Crizotinib (250 mg twice daily)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><b>Pattern:</b></td><td rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (estimated R=~100)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><b>Severity:</b></td><td rowspan="1" colspan="1" style="vertical-align:top;">5+ (hepatic failure and death)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><b><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</b></td><td rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><b>Recovery:</b></td><td rowspan="1" colspan="1" style="vertical-align:top;">None</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><b>Other medications:</b></td><td rowspan="1" colspan="1" style="vertical-align:top;">Not listed</td></tr></tbody></table></div></div></div><div id="Crizotinib.Laboratory_Values2"><h4>Laboratory Values</h4><div id="Crizotinib.T4" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548638/table/Crizotinib.T4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Crizotinib.T4_lrgtbl__"><table><thead><tr><th id="hd_h_Crizotinib.T4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After Starting*</th><th id="hd_h_Crizotinib.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Crizotinib.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a>* (U/L)</th><th id="hd_h_Crizotinib.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Crizotinib.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a>* (mg/dL)</th><th id="hd_h_Crizotinib.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Crizotinib.T4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0</td><td headers="hd_h_Crizotinib.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Crizotinib.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">19</td><td headers="hd_h_Crizotinib.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">184</td><td headers="hd_h_Crizotinib.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.0</td><td headers="hd_h_Crizotinib.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Crizotinib started</td></tr><tr><td headers="hd_h_Crizotinib.T4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 days</td><td headers="hd_h_Crizotinib.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Crizotinib.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">44</td><td headers="hd_h_Crizotinib.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Crizotinib.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.2</td><td headers="hd_h_Crizotinib.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Crizotinib.T4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">17 days</td><td headers="hd_h_Crizotinib.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Crizotinib.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">2062</td><td headers="hd_h_Crizotinib.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Crizotinib.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.3</td><td headers="hd_h_Crizotinib.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Asymptomatic</td></tr><tr><td headers="hd_h_Crizotinib.T4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">24 days</td><td headers="hd_h_Crizotinib.T4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0</td><td headers="hd_h_Crizotinib.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">6194</td><td headers="hd_h_Crizotinib.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Crizotinib.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.5</td><td headers="hd_h_Crizotinib.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Crizotinib stopped</td></tr><tr><td headers="hd_h_Crizotinib.T4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">31 days</td><td headers="hd_h_Crizotinib.T4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 days</td><td headers="hd_h_Crizotinib.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">~980</td><td headers="hd_h_Crizotinib.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Crizotinib.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">16.8</td><td headers="hd_h_Crizotinib.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Symptomatic</td></tr><tr><td headers="hd_h_Crizotinib.T4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">33 days</td><td headers="hd_h_Crizotinib.T4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9 days</td><td headers="hd_h_Crizotinib.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">~600</td><td headers="hd_h_Crizotinib.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Crizotinib.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">~20.0</td><td headers="hd_h_Crizotinib.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Admitted</td></tr><tr><td headers="hd_h_Crizotinib.T4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">35 days</td><td headers="hd_h_Crizotinib.T4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11 days</td><td headers="hd_h_Crizotinib.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">~400</td><td headers="hd_h_Crizotinib.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Crizotinib.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">~19.4</td><td headers="hd_h_Crizotinib.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Coma</td></tr><tr><td headers="hd_h_Crizotinib.T4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">40 days</td><td headers="hd_h_Crizotinib.T4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">16 days</td><td headers="hd_h_Crizotinib.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">~100</td><td headers="hd_h_Crizotinib.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Crizotinib.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">~25.9</td><td headers="hd_h_Crizotinib.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Died</td></tr><tr><td headers="hd_h_Crizotinib.T4_1_1_1_1 hd_h_Crizotinib.T4_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Crizotinib.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Crizotinib.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;130</b></td><td headers="hd_h_Crizotinib.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Crizotinib.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div><p>*Some values estimated from Figure 1.</p></div><div id="Crizotinib.Comment2"><h4>Comment</h4><p>This patient developed marked serum aminotransferase elevations within 2 to 3 weeks of starting crizotinib, but was asymptomatic and therapy was not stopped until values were found to continue to rise. Despite stopping, she became jaundiced and rapidly developed hepatic failure, coagulopathy, liver coma and died. The abruptness of onset and severe course suggests a direct hepatotoxicity, but is also compatible with idiosyncracy. Routine monitoring was performed, but the results were not obtained until retrospectively from the critical 17 day time point. Listing of other medications, even if not known to be hepatoxic, would be helpful as crizotinib has extensive hepatic metabolism, largely via CYP 3A4 and is susceptible to drug-drug interactions. Use of potent CYP3A inhibitors or inducers should be avoided during crizotinib therapy.</p></div></div></div><div id="Crizotinib.PRODUCT_INFORMATION"><h2 id="_Crizotinib_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Crizotinib.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Crizotinib &#x02013; Xalkori&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antineoplastic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?label=all&#x00026;query=Crizotinib" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Crizotinib.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Crizotinib_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Crizotinib.T5" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548638/table/Crizotinib.T5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Crizotinib.T5_lrgtbl__"><table><thead><tr><th id="hd_h_Crizotinib.T5_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Crizotinib.T5_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Crizotinib.T5_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Crizotinib.T5_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Crizotinib.T5_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Crizotinib</td><td headers="hd_h_Crizotinib.T5_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135264650" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">877399-52-5</a></td><td headers="hd_h_Crizotinib.T5_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C21-H22-Cl2-F-N5-O</td><td headers="hd_h_Crizotinib.T5_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548638/bin/Crizotinib_structure.jpg" alt="Crizotinib Chemical structure" /></div></td></tr></tbody></table></div></div></div><div id="Crizotinib.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Crizotinib_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 30 October 2017</p><p>Abbreviations used: NSCLC, non-small cell lung cancer; ALK, anaplastic lymphoma kinase.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Crizotinib.R1">Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.<div><i>(Review of hepatotoxicity published in 1999 before the availability of tyrosine kinase receptor inhibitors).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R2">DeLeve LD. Kinase inhibitors. Gefitinib. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, p. 556.<div><i>(Review of hepatotoxicity of cancer chemotherapeutic agents; crizotinib is listed as causing moderate-to-severe aminotransferase elevations in 4-7% of patients and as having caused fatal hepatotoxicity in some instances).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R3">Chabner BA, Barnes J, Neal J, Olson E, Mujagic H, Sequist L, Wilson W, et al. Targeted therapies: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1731-54.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R4">Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-703.  [<a href="/pmc/articles/PMC3014291/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3014291</span></a>] [<a href="/pubmed/20979469" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20979469</span></a>]<div><i>(Screening 1500 patients identified 82 with ALK-positive non-small cell lung cancer [NSCLC], 47 of whom responded at least partially to crizotinib; common side effects were nausea, diarrhea, visual blurring, constipation and fatigue; ALT or AST elevations of above 5 times ULN occurred in 5 patients [5%], all except one of whom could restart the drug at a lower dose without recurrence).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R5">Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-9.  [<a href="/pmc/articles/PMC3936578/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3936578</span></a>] [<a href="/pubmed/22954507" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22954507</span></a>]<div><i>(Among 149 patients with NSCLC with ALK mutations treated with crizotinib, 61% had an objective response and 97% had at least one adverse event, the most common being visual effects [64%], nausea [56%] and diarrhea [50%], with ALT elevations occurring in 10% and being above 5 times ULN in 3%; among 46 deaths, none were considered drug related).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R6">Girard N. Crizotinib in ALK-positive lung cancer. Lancet Oncol 2012; 13: 962-3.  [<a href="/pubmed/22954506" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22954506</span></a>]<div><i>(Editorial in response to Camidge [2012] with no discussion of potential for hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R7">Crizotinib (Xalkori) for non-small cell lung cancer. Med Lett Drugs Ther 2012; 54 (1383): 11-2.  [<a href="/pubmed/22354221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22354221</span></a>]<div><i>(Concise review of mechanism of action, efficacy, safety and costs of crizotinib shortly after its accelerated approval in the US; mentions rare, but sometimes severe adverse effects of pneumonitis and QTc prolongation, but does not mention hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R8">Ripault MP, Pinzani V, Fayolle V, Pageaux GP, Larrey D. Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose. Clin Res Hepatol Gastroenterol 2013; 37: e21-3.  [<a href="/pubmed/23182672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23182672</span></a>]<div><i>(69 year old woman with NSCLC developed fatigue and ALT elevations 8 weeks after starting crizotinib [ALT 159 U/L, bilirubin and Alk P normal], resolving within 6 weeks of stopping and recurring [ALT 175 U/L] with restarting: Case 1).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R9">Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol 2013; 31: 1105-11.  [<a href="/pmc/articles/PMC4209068/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4209068</span></a>] [<a href="/pubmed/23401436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23401436</span></a>]<div><i>(Review of the history of discovery of ALK mutations and development of crizotinib as therapy of NSCLC patients with this mutation; no discussion of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R10">Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013; 36: 491-503.  [<a href="/pubmed/23620168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23620168</span></a>]<div><i>(Review of the hepatotoxicity of 18 tyrosine kinase inhibitors approved for use in cancer in the US as of 2013; crizotinib is listed as causing liver enzyme elevations in up to 57% of patients [above 5 times ULN in 6%] and having been linked to cases of hepatitis and fatal hepatic failure).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R11">Timm A, Kolesar JM. Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm 2013; 70: 943-7.  [<a href="/pubmed/23686600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23686600</span></a>]<div><i>(Review of role of crizotinib in therapy of NSCLC mentions that ALT elevations above 5 times ULN occur in 6.7% of patients). </i></div></div></li><li><div class="bk_ref" id="Crizotinib.R12">Shaw AT, Kim DW, Nakagawa K, Seto T, Crin&#x000f3; L, Ahn MJ, De Pas T, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-94.  [<a href="/pubmed/23724913" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23724913</span></a>]<div><i> (Among 347 adults with refractory, advanced, ALK-positive lung cancer treated with crizotinib [250 mg twice daily] or conventional chemotherapy [pemetrexed or docetaxel intravenously every 3 weeks], progression free survival was longer with crizotinib [7.7 vs 3 months] and adverse events included ALT or AST elevations in 38% vs 15%, which were above 5 times ULN in 16% vs 2%, and one patient [0.5%] died of liver failure).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R13">Moss&#x000e9; YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013; 14: 472-80.  [<a href="/pmc/articles/PMC3730818/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3730818</span></a>] [<a href="/pubmed/23598171" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23598171</span></a>]<div><i>(Among 79 children with various forms of refractory solid tumors or lymphomas treated with one of 6 doses of crizotinib, ALT elevations occurred in 62% of patients with the first cycle and were above 5 times ULN in 4%; no mention of clinically apparent lier injury).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R14">Sato Y, Fujimoto D, Shibata Y, Seo R, Suginoshita Y, Imai Y, Tomii K. Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma. Jpn J Clin Oncol 2014; 44: 872-5.  [<a href="/pubmed/24966207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24966207</span></a>]<div><i>(54 year old woman with advanced, ALK-positive lung cancer developed malaise 29 days after starting crizotinib [bilirubin 2.7 rising to 4.7 mg/dL, ALT 5201 U/L, Alk P 506 U/L, prothrombin index less than 10%], with progressive liver failure and death 6 days after presentation).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R15">Tsukita Y, Fukuhara T, Kobayashi M, Morita M, Suzuki A, Watanabe K, Noguchi T, et al. Alternate-day treatment with crizotinib for drug-induced esophagitis and liver damage in a patient with EML4-ALK fusion gene-positive lung adenocarcinoma. Intern Med 2015; 54: 3185-8.  [<a href="/pubmed/26666609" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26666609</span></a>]<div><i> (44 year old woman with refractory, metastatic ALK-positive lung cancer developed esophagitis and ALT elevation shortly after starting crizotinib, which improved upon stopping and did not recur on restarting at a reduced dose [alternative day, actual dose not given]).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R16">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 49 cases [6%] were attributed to antineoplastic agents, including 9 due to kinase inhibitors such as imatinib and lapatinib, but none were attributed to crizotinib).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R17">van Geel RM, Hendrikx JJ, Vahl JE, van Leerdam ME, van den Broek D, Huitema AD, Beijnen JH, et al. Crizotinib-induced fatal fulminant liver failure. Lung Cancer 2016; 93: 17-9.  [<a href="/pubmed/26898609" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26898609</span></a>]<div><i>(62 year old woman with advanced, ALK-positive NSCLC developed liver test abnormalities [ALT 2062 U/L] followed by jaundice one week later [bilirubin 1.5 rising to 26.3 mg/dl], hepatic failure and death 40 days after starting and 2 weeks after stopping crizotinib: Case 2).</i></div></div></li><li><div class="bk_ref" id="Crizotinib.R18">Zhang Q, Qin N, Wang J, Lv J, Yang X, Li X, Nong J, et al. Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma. Thorac Cancer 2016; 7: 3-8.  [<a href="/pmc/articles/PMC4718131/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4718131</span></a>] [<a href="/pubmed/26816533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26816533</span></a>]<div><i> (Among 19 patients with previously-untreated, advanced, ALK-positive lung cancer treated with crizotinib compared to 12 patients given conventional chemotherapy, overall response rates were higher with crizotinib [83% vs 25%], but side effects were greater including visual disturbances, diarrhea and abnormal "liver function" in 28% vs 8%; no mention of clinically apparent liver injury).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548638</span><span class="label">PMID: <a href="/pubmed/31643950" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643950</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Corticosteroids/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Crofelemer/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548638&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548638/?report=reader">PubReader</a></li><li><a href="/books/NBK548638/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548638" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548638" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Crizotinib. [Updated 2017 Oct 30].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548638/pdf/Bookshelf_NBK548638.pdf">PDF version of this page</a> (133K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Crizotinib+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Crizotinib: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Crizotinib" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Crizotinib: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4867612" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4867612" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4867612" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643879" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lorlatinib</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lorlatinib<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643391" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alectinib</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alectinib<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31644146" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gefitinib</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gefitinib<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643726" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Erlotinib</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Erlotinib<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643841" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Brigatinib</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Brigatinib<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643950" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643950" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60467d839e31203af657235a">Crizotinib - LiverTox</a><div class="ralinkpop offscreen_noflow">Crizotinib - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:39:47-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal102&amp;ncbi_phid=CE89C02A04664A810000000005A2019C&amp;ncbi_session=CE89C02A0467D821_1442SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548638%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548638&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548638/&amp;ncbi_pagename=Crizotinib - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE89C02A0467D821_1442SID /projects/books/PBooks@9.2 portal102 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>